Alternatively Spliced Human Tissue Factor and Thrombotic Tendencies in Hemodialysis Patients

Authors

Susan Zawaski1, Mary Hammes2,*, Viji Balasubramanian3
1Illinois, USA
2Section of Nephrology, Department of Medicine, University of Chicago, [email protected], USA
3Department of Biomedical Engineering, Illinois Institute of Technology, USA
*Corresponding Author: Section of Nephrology, Department of Medicine, University of Chicago, [email protected], USA. Tel: 773-702-9892. Email: [email protected]

Nephro-Urology Monthly:Vol. 2, issue 1; 193-199
Published online:Jan 31, 2010
Article type:Research Article
Received:Jun 28, 2009
Accepted:Jul 27, 2009
How to Cite:Zawaski S, Hammes M, Balasubramanian V. Alternatively Spliced Human Tissue Factor and Thrombotic Tendencies in Hemodialysis Patients. Nephro-Urol Mon. 2010;2(1):. doi:

Abstract

Background and Aims: Chronic hemodialysis (HD) patients are associated with an increased thrombotic tendency, a frequent and costly cause of morbidity in this patient population. HD patients often have multiple defects in their hematologic/coagulation factors; however, few convincing associations have been made between these abnormalities and clinical thrombotic events. Alternatively spliced human tissue factor (asHTF), a recently discovered soluble form of tissue factor (TF), circulates in blood and exhibits procoagulant activity. Therefore, the present investigation was designed to initially determine if asHTF levels are correlated to thrombotic tendencies in HD patients.

Methods: Pre-dialysis blood samples were drawn from a cohort of 84 hemodialysis patients immediately prior to dialysis. Plasma asHTF levels were quantified and then compared to a variety of patient parameters collected for each patient.

Results: Mean plasma asHTF levels for HD patients varied significantly compared to 30 healthy normal subjects. We found a positive correlation between asHTF concentration and access thrombosis in hemodialysis patients (r =0.31, p =0.0046). When patients without any episodes of thrombosis were excluded, correlation increased (r =0.59, p =0.0001). The patient with the highest number of incidences of thrombosis (n=25) also had the highest plasma asHTF concentration (1066.61 pg/ml), over seven standard deviations above the mean.

Conclusion: These initial results suggest that plasma asHTF antigen levels may be associated with access thrombosis in HD patients. Further studies are needed to confirm our findings and to determine whether elevated asHTF levels indicate a causal or responsive role in HD associated access thrombosis.

Full Text

Full text is available in PDF

Copyright

© 2010, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

30
Apr
2010

Prothrombin, Factor-V Leiden, and Plasminogen Activator Inhibitor Type 1 Gene Polymorphisms in Hemodialysis Patients with/without Arteriovenous Fistula Thrombosis

Elif Funda Emirogullari,
Cetin Saatci,
Aydin Unal,
Atilla Sahin,
Yusuf Ozkul1

Emirogullari E, Saatci C, Unal A, Sahin A, Ozkul1 Y. Prothrombin, Factor-V Leiden, and Plasminogen Activator Inhibitor Type 1 Gene Polymorphisms in Hemodialysis Patients with/without Arteriovenous Fistula Thrombosis. Nephro-Urol Mon. 2010;2(2):. doi:

24
Mar
2009

Correlation of thrombotic factor with bleeding severity in patient’s with factor XI deficiency

Mohammad Faranosh,
Ali JafarPor,
Mahbobeh Rahmani,
Mohammad Jazebi,
Tahereh Shasani,
Navid Danaie
,et al.

Faranosh M, JafarPor A, Rahmani M, Jazebi M, Shasani T, et al. Correlation of thrombotic factor with bleeding severity in patient’s with factor XI deficiency. koomesh. 2009;11(1):e152264. doi:

30
Sep
2008

Survey of the relationship between of thrombophilic factors and the rate and severity of bleeding in patients with severe hemophilia A

Mohammad Faranosh,
Navid Danayie,
raheb Ghorbani,
Mahbobeh Rahamani,
Mohammad Jazebi,
Tahere Shashani
,et al.

Faranosh M, Danayie N, Ghorbani R, Rahamani M, Jazebi M, et al. Survey of the relationship between of thrombophilic factors and the rate and severity of bleeding in patients with severe hemophilia A. koomesh. 2024;9(4):e152211. doi:

11
Nov
2014

Von Willebrand Factor-Cleaving Protease Activity in Thrombotic Microangiopathy: First Report From Iran

Mohammadreza Ardalan,
Parisa Rezaeifar

Ardalan M, Rezaeifar P. Von Willebrand Factor-Cleaving Protease Activity in Thrombotic Microangiopathy: First Report From Iran. Nephro-Urol Mon. 2014;6(6):e18900. doi: https://doi.org/10.5812/numonthly.18900

22
Jun
2022
Coagulation Factor VII: Genetic, Molecular, and Clinical Characteristics

Coagulation Factor VII: Genetic, Molecular, and Clinical Characteristics

Amir Mashayekhi,
Ezatollah Ghasemi

Mashayekhi A, Ghasemi E. Coagulation Factor VII: Genetic, Molecular, and Clinical Characteristics. J Adv Immunopharmacol. 2022;2(1):e128397. doi: https://doi.org/10.5812/tms-128397

More by these authors

Susan ZawaskiPubMedScholar
Mary HammesPubMedScholar
Viji BalasubramanianPubMedScholar
Share
Cited by
Metrics